ABVC BioPharma Q3 2025 licensing revenue up 230% YoY to $1.28M; total assets rise 181%

ABVC BIOPHARMA, INC.

2025-Q3 EPS reported -$0.23 revenue$795,950

Licensing revenue of $1.28M in Q3 2025 vs $0.39M in Q3 2024 (+230% YoY).
Total assets $21.18M (Sep 30, 2025) vs $7.54M (Dec 31, 2024); up 181%.
Property and equipment surged to $12.06M from $0.51M (+2,100%) on land buys in Taiwan.
Two land acquisitions completed in Q3: Puli ($7.67M) and Longtan ($3.3M) for R&D and API cultivation.
Company maintains asset-light licensing model with multiple CNS, ophthalmology, oncology licensing agreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.